Free Trial

Maravai LifeSciences (MRVI) 10K Form and Latest SEC Filings 2026

Maravai LifeSciences logo
$4.83 +0.89 (+22.69%)
As of 12:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Maravai LifeSciences SEC Filings & Recent Activity

Maravai LifeSciences (NASDAQ:MRVI) has submitted 252+ documents to the U.S. Securities and Exchange Commission (SEC) since 2020. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Maravai LifeSciences's financial statements. The most recent filing was a Form 8-K submitted on May 7, 2026.

Form 4
MARAVAI LIFESCIENCES HOLDINGS, INC. Reports Ownership Change on Mar. 17, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Maravai LifeSciences Files Current Report on May. 7, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Maravai LifeSciences Files Annual Report on Feb. 26, 2026

The 10-K contains Maravai LifeSciences's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Maravai LifeSciences SEC Filing History

Browse Maravai LifeSciences' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/07/2026 3:05 PM
Maravai LifeSciences (1823239) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/27/2026 7:00 PM
Maravai LifeSciences (1823239) Filer
Form DEFA14A
04/24/2026 3:40 PM
Maravai LifeSciences (1823239) Filer
Form ARS
04/24/2026 3:29 PM
Maravai LifeSciences (1823239) Filer
Form DEF 14A
03/17/2026 3:16 PM
Maravai LifeSciences (1823239) Issuer
ORESHACK KURT (1832579) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/17/2026 3:16 PM
Dolan Christine (1684273) Reporting
Maravai LifeSciences (1823239) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2026 3:06 PM
Maravai LifeSciences (1823239) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/17/2026 9:30 AM
12 West Capital Management LP (1540531) Filed by
Maravai LifeSciences (1823239) Subject
Form SCHEDULE 13G/A
01/20/2026 4:28 PM
Maravai LifeSciences (1823239) Issuer
ORESHACK KURT (1832579) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/20/2026 4:28 PM
Dolan Christine (1684273) Reporting
Maravai LifeSciences (1823239) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2025 3:38 PM
Hopfield Jessica (1648715) Reporting
Maravai LifeSciences (1823239) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/09/2025 3:36 PM
LUCIER GREGORY T (1251299) Reporting
Maravai LifeSciences (1823239) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/17/2025 3:48 PM
Brust Bernd (1380632) Reporting
Maravai LifeSciences (1823239) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2025 8:31 AM
FELDMAN STUART (1237237) Filed by
Maravai LifeSciences (1823239) Subject
Form SCHEDULE 13G/A
11/13/2025 4:27 PM
Brust Bernd (1380632) Reporting
Maravai LifeSciences (1823239) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/07/2025 3:21 PM
Maravai LifeSciences (1823239) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/31/2025 10:04 AM
Maravai LifeSciences (1823239) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
10/27/2025 3:23 PM
Maravai LifeSciences (1823239) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/17/2025 5:13 PM
BlackRock, Inc. (2012383) Filed by
Maravai LifeSciences (1823239) Subject
Form SCHEDULE 13G/A
07/18/2025 3:45 PM
Maravai LifeSciences (1823239) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/16/2025 3:21 PM
Leddy Peter Michael (1332202) Reporting
Maravai LifeSciences (1823239) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/11/2025 4:40 PM
LUCIER GREGORY T (1251299) Reporting
Maravai LifeSciences (1823239) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/30/2025 5:04 PM
Asarpota Rajesh (1600301) Reporting
Maravai LifeSciences (1823239) Issuer
Form 3
Initial statement of beneficial ownership of securities  
06/30/2025 5:04 PM
Asarpota Rajesh (1600301) Reporting
Maravai LifeSciences (1823239) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/25/2025 3:13 PM
Maravai LifeSciences (1823239) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/18/2025 5:23 PM
DeFord John A (1403373) Reporting
Maravai LifeSciences (1823239) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025 5:24 PM
Hopfield Jessica (1648715) Reporting
Maravai LifeSciences (1823239) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025 5:24 PM
Maravai LifeSciences (1823239) Issuer
MIHAS CONSTANTINE S (1262930) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025 5:24 PM
ECKERT R ANDREW (1210525) Reporting
Maravai LifeSciences (1823239) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025 5:24 PM
CUNNINGHAM SEAN LAURENCE (1829753) Reporting
Maravai LifeSciences (1823239) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025 5:24 PM
Maravai LifeSciences (1823239) Issuer
PRAHALAD MURALI (1829991) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025 5:24 PM
LUCIER GREGORY T (1251299) Reporting
Maravai LifeSciences (1823239) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025 5:25 PM
Maravai LifeSciences (1823239) Issuer
MARKER LUKE JOSEPH (1829810) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025 5:25 PM
GRAY SUSANNAH (1833453) Reporting
Maravai LifeSciences (1823239) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025 5:25 PM
DAVERMAN BENJAMIN JAMES (1829768) Reporting
Maravai LifeSciences (1823239) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025 4:26 PM
Brust Bernd (1380632) Reporting
Maravai LifeSciences (1823239) Issuer
Form 3
Initial statement of beneficial ownership of securities  
06/10/2025 4:29 PM
Brust Bernd (1380632) Reporting
Maravai LifeSciences (1823239) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 7:40 AM
Maravai LifeSciences (1823239) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/29/2025 4:24 PM
FELDMAN STUART (1237237) Filed by
Maravai LifeSciences (1823239) Subject
Form SCHEDULE 13G
05/28/2025 4:51 PM
Dolan Christine (1684273) Reporting
Maravai LifeSciences (1823239) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2025 4:52 PM
Herde Kevin (1671595) Reporting
Maravai LifeSciences (1823239) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2025 4:26 PM
Maravai LifeSciences (1823239) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/12/2025 3:28 PM
Maravai LifeSciences (1823239) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Maravai LifeSciences SEC Filings - Frequently Asked Questions

Maravai LifeSciences (MRVI) has submitted 252+ filings to the SEC since 2020. You can browse the complete history or filter by form type using the tools above.

Maravai LifeSciences's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Maravai LifeSciences's financial statements page.

The most recent filing was a Form 8-K submitted on May 7, 2026. This was a current report on a material business event.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:MRVI) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners